BMJ Open Chinese physicians' attitudes toward eco-directed sustainable prescribing from the perspective of ecopharmacovigilance: a cross-sectional study

Jun Wang,¹ Shulan Li,¹ Bingshu He ²

To cite: Wang J, Li S, He B. Chinese physicians' attitudes toward eco-directed sustainable prescribing from the perspective of ecopharmacovigilance: a cross-sectional study. *BMJ Open* 2020;**10**:e035502. doi:10.1136/bmjopen-2019-035502

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2019-035502>).

Received 04 November 2019

Revised 21 February 2020

Accepted 14 May 2020

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Wuhan University of Science and Technology, Wuhan, Hubei, China

²Orthopedic Surgery, Hubei Province Woman and Child Hospital, Wuhan, Hubei, China

Correspondence to

Dr Bingshu He;
hbs102626@163.com

ABSTRACT

Introduction Eco-directed sustainable prescribing (EDSP) is an effective upstream way to reduce the environmental footprints of active pharmaceutical ingredients (APIs), a kind of emerging contaminants, from the patients' excretion. EDSP is one of the key steps in the programme of ecopharmacovigilance (EPV), a drug administration route on API pollution.

Objective To assess the attitudes of physicians prescribing medicines regarding EDSP from the perspective of EPV.

Design A cross-sectional study conducted from March 2019 to June 2019.

Setting 5 government general hospitals in Hubei province, China.

Participants 405 physicians were randomly selected and 262 valid questionnaires were obtained.

Outcome measures A self-developed questionnaire, which inquired about the participant characteristics, perceptions and attitudes toward API pollution, EPV and EDSP from an EPV perspective, was emailed to collect data from physicians.

Results Most physicians agreed the existence of APIs in environment, worried about the potential environmental and ecological risks of API residues, supported the effectiveness and necessity of EDSP under an EPV perspective in decreasing environmental exposure of excreted APIs, and showed their willingness to participate in the EDSP practices. Nevertheless, no respondent identified the environmental impacts as the aspects regarding medicines affecting his(her) prescription decision, none was satisfied with knowledge on EDSP and showed confidence toward EDSP. The most important barrier to the effective implementation of EDSP was identified as 'poor awareness of EDSP and EPV'. Most responding physicians (97%) reported that they held the wait-and-see or conservative attitudes towards EDSP practice. The biggest concerns in *low-dose prescribing* and *prescribing of drugs possessing environment-friendly excretion profiles*, two EDSP approaches, were the possible negative impact on therapeutic outcomes and too complicated and professional drug evaluation process, respectively.

Conclusions Chinese physicians had positive attitudes towards EDSP from the perspective of EPV. However, their environmental consciousness during prescribing and the related education were insufficient.

Strengths and limitations of this study

- To the best of our knowledge, this is the first study that explored the physicians' perceptions and attitudes toward eco-directed sustainable prescribing (EDSP) from the perspective of ecopharmacovigilance (EPV), a sustainable prescription approach to minimise the environmental loads and risks of excreted active pharmaceutical ingredient residues at their sources.
- Based on the survey results, we proposed some recommendations for further implementing EDSP from the perspective of EPV in practice.
- The main limitation of this study is the sampling bias.

INTRODUCTION

The occurrence of active pharmaceutical ingredients (APIs), a kind of emerging contaminants without standard regulations, in the environment worldwide has become an issue of special importance.^{1–5} As a drug administration route on environment pollution caused by APIs, ecopharmacovigilance (EPV) is an emerging science of detection, evaluation, understanding and prevention of the adverse effects of APIs in the environment.^{6–14} In recent years, an approach termed eco-directed sustainable prescribing (EDSP),¹⁵ which was proposed to prevent the adverse effects of APIs in the environment resulting from medical prescriptions, has been well-accepted as an indispensable part during EPV implementation.^{8 12 13} However, EDSP might conflict with long-accepted clinical prescribing guidelines and tenet. It is necessary to explore the attitudes of prescribers toward EDSP.¹⁵

As a critical part of modern life, pharmaceutical drugs are abundantly used in healthcare practices around the world.⁵ The environmental discharge of APIs in a continuous and unsupervised way as well as their inadequate

removal during wastewater treatment processes have led to their detection in the various environmental matrices at levels of concern.^{2–5} Considering their potent biological activities even at very low concentrations, API residues have been recognised to pose potential risks and hazards to the natural environment, ecology and human health due to long-term exposures.^{6–18} Therefore, it is urgent to address this issue, aiming to minimise the environmental loads and risks of API residues. Based on the fact that API pollution could be ultimately traced back to the use of medications in healthcare practices, EPV focusses on the clinical application of active pharmaceutical management strategies to decrease the API emission at the sources and minimise the environmental footprint of the healthcare industry.^{9–13} The sources of APIs in environment include excretion from drug-consuming patients and animals, inappropriate deposition of expired or unwanted pharmaceutical products, manufacturing plant wastes, hospital wastes, and so on.^{19–23} Thereinto, patients' excretion in forms of parent APIs or active metabolites has been well-accepted to constitute the major contribution to most API pollutants in the environment.^{15–24–26}

Since normal physiological excretion of APIs in drug-consuming patients cannot be prevented, the optimised administration of pharmaceuticals ensuring satisfactory but not too high pharmacologically active concentrations in patients might be a key protective measure against excessive API entry to the environment from excretion.^{15–27–29} Driven by this idea, EDSP was recommended by Daughton¹⁵ to reduce the environmental load of excreted APIs. As prescribers are commonly confronted with more than one choice of drug treatment,³⁰ EDSP provides a new and more established decision support system to include environmental considerations in drug prescription. The term of EDSP is used to describe the combination of two prescription optimisation methods—*low-dose prescribing* and *prescribing of drugs possessing environment-friendly excretion profiles*. The dose of drugs prescribed plays a paramount role on the quantities of APIs entering into the environment.³¹ Certainly, any reduction in prescription of API would lead to a proportional reduction in excreted APIs released into wastewater.^{15–27–32} Moreover, lower doses also hold the potential to eliminate the subsequent need for disposal of leftovers, relieve the adverse events associated with drug overdose, improve patient/physician communication, avoid the accidental exposures as well as reduce healthcare costs.^{15–27} On the other hand, EDSP places an additional emphasis on the metabolism and excretion profiles of drugs rather than only the dose initially used by the patient. Within a same therapeutic class, and with similar therapeutic efficacies, more extensively metabolisable medicines which have more environment-friendly excretion profiles resulting in less excretion of bioactive API residues would produce more negligible environmental footprints, thus could be favoured for EDSP.^{15–25} EDSP has been endorsed by International Pharmaceutical Federation³³ as a means to promote the sustainable application of drugs.

However, the translation of EDSP concept into a clinical practice will mean to change the conventional prescribing behaviour of physicians, which would certainly be a major challenge.^{15–25–34} The opinions toward EDSP held by prescribers play a pivotal role in determining its acceptability and its future application. China is a populous country where prescribing practices of physicians may have a significant impact on the global environment. In order to explore the attitudes of prescribers toward EDSP and their willingness of participation, the present study was carried out among Chinese physicians prescribing medications in Hubei, a province located in Central China, to assess the physicians' attitudes toward EDSP from the perspective of EPV and obtained some interesting findings. This is an innovative subject and may contribute to policy development.

METHODS

Study design

A descriptive, cross-sectional survey involving authorised physicians presently working at government general hospitals in Hubei province, China, who were willing to participate in the study, was undertaken to assess their perceptions about API pollution in environment and EPV, in particular, their attitudes toward EDSP using a self-developed questionnaire. The study was conducted for over a period of 4 months from March 2019 to June 2019.

Study population

The initial list of about 809 physicians distributed among five hospitals was used as the target sampling frame. The sampling of the hospitals was a convenient one, determined by the proximity of the hospital administrators to the authors. From this list, 405 physicians were randomly selected for inclusion in this survey using an 2:1 proportion.

The sample size was determined by considering the availability of subjects and the feasibility of enrolling physicians. A review of the existing literature^{35–38} indicated a sample size of 200 to 400 physicians would be adequate to ensure data analysis and generalisability of responses.

Questionnaire development

A self-developed questionnaire was used in this study, since there is no standardised material available for testing attitudes about EDSP. The initial draft of the survey questionnaire was developed using information from the relevant published studies regarding API pollution in environment,^{1–15–16–26} EPV^{6–14} and EDSP^{15–25–27–29} after performing a thorough literature review. The initial questions were devised, developed and refined for clarity by all authors during several in-person group discussions.

The respondents were informed about the basic concepts of EPV and EDSP on the first page of the questionnaire. A total of 25 structured questions divided into three sections were included in the survey questionnaire,

which required about 10 to 15 min to complete. The first section consisted of five questions about respondent physicians' socio-demographic characteristics, including gender, age, education background, speciality and years of experience. The second section included seven question items designed to capture the perceptions toward API pollution in environment and EPV. A 5-point Likert-scale format was used in the data collection in this section (1: strongly disagree, 2: disagree, 3: neutral, 4: agree and 5: strongly agree). The third section of the survey questionnaire included 13 items designed to assess the physicians' perceptions and attitudes toward EDSP from the perspective of EPV.

Two specialists in the investigative field were asked to evaluate the clarity, content validity, relevance and conciseness of the items in the questionnaire. For validation of the questionnaire, pretesting of the questionnaire was done on a convenient sample of 20 physicians, who were not included in the final survey, to examine the validity and the acceptability of the questionnaire. After discussion and a minor modification, the final survey questionnaire was approved with overall and separate Cronbach's alpha values, and Kaiser-Meyer-Olkin (KMO) measures >0.700. The final questionnaire was developed in English as the original language, then translated into Chinese and back into English.

Data collection

The developed questionnaire was mailed to collect data from the physicians *via* email addresses provided by the hospital administrators. A confirmation email together with an explanatory letter about the survey's purpose and objectives were sent to the respondents first. After returning their confirmation letters, the responding physicians received copies of the electronic questionnaire *via* email, and were requested to complete the questionnaire and then return it within next 3 days to the researchers. Two weeks after sending the questionnaire, a follow-up reminder postcard was sent to the non-responders to increase the response rate. Each respondent participated in the survey voluntarily. All questionnaires were checked by JW and SL to ensure the data quality. Those who were not willing to participate in or did not return the completed questionnaires within the stipulated time period were excluded from this study.

Statistical analysis

The collected data were entered into SPSS 20.0 for analysis. Results were presented as numbers (percentages) for categorical variables and mean (SD) for quantitative variables. Reliability and validity of the questionnaire were assessed using Cronbach's alpha coefficient and Bartlett's test of sphericity/KMO measures, respectively. Any relationship between the categorical data was determined using χ^2 test or Fisher's exact test. Independent t-test was applied to compare the mean perception scores of the two groups. The differences between pairwise groups were detected using the one-way analysis of

Table 1 Demographic information and knowledge score of Chinese physicians participating in the study (n=262)

Participant characteristics	Respondents no. (%)
Gender	
Male	124 (47)
Female	139 (53)
Age	
20–40 years	125 (48)
>40 years	137 (52)
Postgraduate training	
Yes	170 (65)
No	92 (35)
Job category	
Internal medicine	102 (39)
Surgery	98 (37)
Others	62 (24)
Years of experience	
≤10	92 (35)
11–20	96 (37)
>20	74 (28)

variance (ANOVA) with post hoc Tukey's honestly significant difference (HSD) analysis for multiple comparisons. Differences were statistically significant when the p value was less than 0.05.

Patient and public involvement

Patients and the public were not involved in the design and the conception of this study.

RESULTS

Respondents' characteristics

By the end of the study period, 284 (71%) of 405 randomly selected Chinese physicians had agreed to participate and responded to the survey, yielding 262 completed questionnaires available for analysis (overall effective response rate: 65%). The respondents' age ranged between 25 and 63 years with a mean of 43.6 (SD: 12.3) years. Table 1 presented the demographic information of respondents. The gender, age, speciality or years of experience in distribution of physician respondents was approximately equal. Majority of respondents (65%) held postgraduate qualifications, which was in accordance with the popularisation and advances of medical postgraduate education in China.³⁹

Reliability and validity of the questionnaire

The overall Cronbach's alpha and KMO values were obtained as 0.788 and 0.716, respectively. For the reliability of separate items of *API pollution in environment*, *EPV* and *EDSP*, the Cronbach's alpha values were 0.801, 0.792 and 0.865. The result for Bartlett's test of sphericity was $\chi^2_{(190)}=938.8$ and was statistically significant ($p<0.001$),

Table 2 Chinese physicians' perceptions toward API pollution in environment and EPV (n=262)

Survey question/statement	Respondents no. (%)				
	Strongly agree	Agree	Undecided	Disagree	Strongly disagree
Q1: APIs used in healthcare practices could finally enter into the environment.	96 (37)	113 (43)	45 (17)	8 (3)	0 (0)
Q2: API residues in environment could cause adverse effects on ecosystem, wildlife species, even human beings.	126 (48)	108 (41)	26 (10)	2 (1)	0 (0)
Q3: It is necessary to minimise the entrance of APIs into the environment.	104 (40)	125 (48)	31 (12)	2 (1)	0 (0)
Q4: The control of API pollution is none of my business, because it should be the responsibility of environmental experts and regulators.	5 (2)	6 (2)	73 (28)	80 (31)	98 (37)
Q5: API pollution could be ultimately traced back to the use of medications in healthcare practices.	113 (43)	96 (37)	50 (19)	3 (1)	0 (0)
Q6: If there is an upstream intervention for controlling API entry to the environment, I would endorse it, and be very pleased to participate in its implementation.	68 (26)	99 (38)	94 (36)	1 (0)	0 (0)
Q7: Based on the description of EPV given on the first page of this questionnaire, I think EPV is an effective tool to control API entry to the environment.	83 (32)	74 (28)	98 (37)	5 (2)	2 (1)

APIs, active pharmaceutical ingredients; EPV, ecopharmacovigilance.

suggesting a factorable intercorrelation matrix. For the construct validity of separate items of *API pollution in environment*, *EPV* and *EDSP*, KMO measures were 0.741, 0.789 and 0.712, respectively.

Perceptions toward API pollution in environment and EPV

The perceptions toward API pollution and EPV were collected from 262 physicians using 5-point Likert scales. Data shown in [table 2](#) revealed that the responding physicians' overall perceptions towards API pollution in environment and EPV was positive. Most respondents (80%, 89%, 88% and 80%, respectively) agreed or strongly agreed the entry of API residues into the environment (Q1), their environmental and ecological adverse effects (Q2), the necessity to minimise the entrance of APIs into the environment (Q3), as well as the importance of the administration of medication use in healthcare practices for the API pollution control (Q5). As for the reverse-score item indicating the control of API pollution is not physicians' responsibility (Q4), only 4% respondents agreed, suggesting most physicians realised their own responsibility in the control of API pollution. Then the physicians were asked about whether they agree with EPV, an upstream intervention for controlling API entry to the environment (Q6 and Q7). It was encouraging to find that 60% believed that EPV is an effective tool to control API entry to the environment, and 64% claimed that they would endorse and be very pleased to participate in. However, there were a considerable portion (36% to 37%) of respondents felt undecided, suggesting their uncertainty regarding EPV. The results of the univariate analysis using independent t-test or one-way ANOVA test of the above variables in perceptions with regards

to the respondents' gender, age, education background, speciality and years of experience groups were not significant ($p>0.05$).

Perceptions and attitudes toward EDSP from the perspective of EPV

Possible factors affecting the physicians' decision process for drug prescription

As shown in [table 3](#), an overwhelming majority (94% to 100%) of physicians supported that efficacy, safety or cost of medicines affected their prescription decisions (Q1), which was in line with the well-accepted traditional rational prescription principle, that is, the selection of drugs should be based on efficacy, safety and cost considerations.^{30 40} However, none was environmentally conscious in their prescribing. As the key basis for EDSP,¹⁵ the evaluation of pharmacokinetic property was incorporated into the prescribing process only by 22% respondents. Nevertheless, it was encouraging that 65% physicians were aware of their responsibilities for reducing API releases to environment, despite the fact that 31% were undecided (Q2). Almost all the physician respondents had not previously heard of EDSP (Q3), however, the effectiveness of EDSP in the control of the entrance of APIs into the environment was agreed or strongly agreed by about half (53%) respondents (Q4).

Physicians' attitudes toward low-dose prescribing and prescribing based on drugs' excretion profiles, two EDSP approaches

Low-dose prescribing is one of two different 'front-of-pipe' approaches under the EDSP design.^{15 25 28 29} According to its theoretical analysis,^{24 25 27} a total of eight possible benefits of low-dose prescribing had been summarised (Q5).

Table 3 Assessment of Chinese physicians' perceptions and attitudes toward EDSP (n=262)

Survey question/statement	Response	Respondents no. (%)
Q1: At present, the aspects regarding medicines affecting my prescription decision include:*	Efficacy	262 (100)
	Safety	258 (98)
	Cost and economy	246 (94)
	Convenience	188 (72)
	Pharmacokinetics	57 (22)
	Marketing and promoting	139 (53)
	Environmental impacts	0 (0)
Q2: As prescribers, physicians bear a responsibility for reducing API releases to environment.	Strongly agree	86 (33)
	Agree	83 (32)
	Undecided	81 (31)
	Disagree	12 (5)
	Strongly disagree	0 (0)
Q3: Previous to this survey, I have heard of EDSP.	Yes	260 (99)
	No	2 (1)
Q4: According to the description on the basic concept of EDSP provided on the first page of this questionnaire, I think EDSP is an effective tool to control the entrance of APIs into the environment.	Strongly agree	54 (21)
	Agree	96 (37)
	Undecided	101 (39)
	Disagree	9 (3)
	Strongly disagree	2 (1)
Q5: I think the benefits of <i>low-dose prescribing</i> include:*	Reducing the environmental loading of API residues from patients' excretions.	257 (98)
	Eliminating the subsequent need and cost for disposal of pharmaceutical leftovers	240 (92)
	Reducing healthcare expenditures for patients.	104 (40)
	Improving therapeutic efficacy via minimising off-target side-effects related to dosage, and thus enhancing pharmaceutical compliance.	75 (29)
	Protecting public health by unintended poisonings by drugs (especially infants, toddlers and children) resulted from inappropriate storage or disposal.	238 (91)
	Reducing drug diversion and the profound problems with attendant abuse of certain drugs and misuse of others.	215 (82)
	Improving public trust—by reducing hidden and unwelcomed exposure of humans to trace levels of numerous APIs via potable water and contaminated foods.	242 (92)
	Improving patient/physician communication.	89 (34)
Q6: My concerns regarding the <i>low-dose prescribing</i> are:*	It can not achieve ideal therapeutic efficacy, and might delay treatment.	262 (100)
	The lowest effective dose with environmental safety is not certain and available.	259 (99)
	It is a new prescribing concept, therefore, a long time will be taken to popularise it in clinical practice.	207 (79)
	It will change my prescribing habits, thus is too troublesome.	55 (21)

Continued

Table 3 Continued

Survey question/statement	Response	Respondents no. (%)
Q7: It is necessary to emphasise on the metabolism and excretion of drugs rather than the initially ingested dose by the patient, because the emission of APIs into the environment via sewers is dictated by the excretion profile and pharmacokinetics of the different types of pharmaceutical compounds.	Strongly agree	79 (30)
	Agree	123 (45)
	Undecided	48 (18)
	Disagree	11 (4)
	Strongly disagree	1 (0)
Q8: My concerns regarding the <i>prescribing of drugs possessing environment-friendly excretion profiles</i> are:*	It can not achieve ideal therapeutic efficacy, and might delay treatment.	35 (13)
	Under the EDSP design, drug evaluation based on the excretion profile and pharmacokinetics is too complicated and professional.	219 (84)
	There is no available accurate data on the excretion profile and pharmacokinetics of drugs.	190 (73)
	It is a new prescribing concept, therefore, a long time will be taken to popularise it in clinical practice.	211 (81)
	It will change my prescribing habits, thus is too troublesome.	62 (24)
Q9: My self-satisfaction with knowledge on EDSP.	Agree	0 (0)
	Disagree	262 (100)
Q10: My confidence toward EDSP.	Agree	0 (0)
	Disagree	262 (100)
Q11: For now, the EDSP behaviour that I want to choose first is:	None. I will take a wait-and-see approach.	134 (51)
	I will promote rational prescribing at precise doses, avoid overprescribing and misprescribing.	121 (46)
	I will implement the low-dose prescribing.	3 (1)
	I will prescribe drugs possessing environment-friendly excretion profiles as much as possible.	4 (2)
Q12: I think the most major perceived barrier to the effective implementation of EDSP under the perspective of EPV in China is:	Poor awareness of EDSP and EPV.	101 (39)
	Lack of an administrative framework for EDSP under the perspective of EPV.	50 (19)
	Lack of available data related to EDSP under the perspective of EPV.	96 (37)
	It conflicts with long-accepted prescribing guidelines.	15 (6)
Q13: I am very pleased to participate in EDSP activities in my future practice if it is successfully translated into clinical treatment.	Strongly agree	85 (32)
	Agree	121 (46)
	Undecided	53 (20)
	Disagree	3 (1)
	Strongly disagree	0 (0)

*Multiple responses were permitted, percentages do not add to 100%.

APIs, active pharmaceutical ingredients; EDSP, eco-directed sustainable prescribing; EPV, ecopharmacovigilance.

Among them, three benefits related to the environmental issues (ie, reducing the API environmental loading from patients' excretions, reducing pharmaceutical leftovers and improving public trust) were supported by most physicians (92% to 98%). However, the improvement on therapeutic efficacy was least recognised as the positive outcome of *low-dose prescribing*. This finding was in accordance with the result that all the respondents worried that

the *low-dose prescribing* could not achieve ideal therapeutic efficacy, and might delay treatment (Q6).

On the other hand, the importance of *prescribing based on drugs' excretion profiles*, the other element of EDSP, was agreed or strongly agreed by a solid majority (75%) of respondents (Q7). However, being different from findings from the same question posed for *low-dose prescribing* (Q6), few (13%) respondents worried about the

therapeutic efficacy of *prescribing on drugs' excretion profiles* (Q8). Most (84%) physicians placed misgivings about the complexity and professionalisation of drug evaluation and EDSP design based on the excretion profile and pharmacokinetics (Q8).

In addition, the availability of the related data as well as the long time period that will be taken to popularise in clinical practice were considered by most respondents (73% to 99%) as physicians' concerns regarding these two ways to achieve EDSP (Q6 and Q8).

Physicians' attitudes toward EDSP

All the responding physicians were not satisfied with knowledge on EDSP (Q9), as well as did not feel confident toward EDSP (Q10). Accordingly, about half (51%) respondents would adopt a wait-and-see approach for EDSP. Furthermore, 46% reported that they would follow conservative EDSP strategies, such as promoting rational prescribing at precise doses, avoiding overprescribing and misprescribing (Q11). The most important perceived barrier to the effective implementation of EDSP under the perspective of EPV in China was 'poor awareness of EDSP and EPV', which was supported by 39% respondents. The lack of available data related to EDSP under the perspective of EPV was ranked as the second important barrier, which was supported by 37% respondents (Q12). A majority of the (78%) respondents claimed that, if EDSP is successfully translated into a clinical treatment, they would be very pleased to participate in the related activities in their future practice (Q13).

Group comparisons

When assessing for differences in demographic factors (gender, age, education background, speciality and years of experience), we only found the responses from two questions (Q1 and Q11) on perceptions and attitudes toward EDSP could be significantly influenced by speciality. Compared with surgeons and physicians in other specialities, the internal medicine physicians appeared to offer significantly more support that the pharmacokinetics of medicines currently affected their prescription decisions (Q1), and want to choose the EDSP behaviours first rather than take a wait-and-see approach (Q11) ($p < 0.01$). In particular, all seven respondents who wanted to implement the *low-dose prescribing* or *prescribe drugs possessing environment-friendly excretion profiles* as much as possible were physicians working in the internal medicine specialities.

DISCUSSION

It has been more than 5 years since the concept of EDSP was first proposed.¹⁵ The indispensable role of EDSP in the practice of EPV, a promising source control strategy for API pollution from the perspective of drug administration, has already been well accepted in theory.^{8 12 13} But unfortunately, this theoretically efficacious solution for the environmental issues caused by excreted APIs is so far still on the conceptual level, and its conceptualisation has

been rarely applied to real cases, which also restricts the empirical domain of EPV. In order to assure and promote the practical application of EDSP and EPV, it is necessary to first explore the acceptance of these new concepts by the involved stakeholders, which is prerequisite to subsequent behavioural change and efficient participation.

In China, the main prescribers were the physicians within healthcare systems. Of course, physicians should be environmentally conscious in their prescribing, and prescribe those drugs that might have minimal environmental impact.⁴¹ Hubei province is one of the national leaders in healthcare industry and pharmaceutical consumption in China.¹⁴ The 2018 China Health Statistical Yearbook reported that, in China, there were 64.4% health workers working in hospitals in 2017, with 81.0% of them in government general hospitals.⁴² Therefore, the physician samples included in this study were randomly selected from five government general hospitals in Hubei province. Demographic data based on gender, age, education background, speciality and years of experience indicated that the surveyed physician samples were generally representative of Chinese physicians.

The emphasis of this survey was to determine the perceptions and attitudes of physicians toward EDSP, an emerging prescribing concept as an environmentally better alternative in the clinical use of medicines.^{15 25} But EDSP has been well-accepted as an essential element of EPV practice in the control of API pollution in environment.^{8 12 13} Therefore, the perceptions toward API pollution and EPV were studied first. The results from table 2 showed the positive overall perception of responding physicians towards API pollution in environment and EPV. Accordingly, it is encouraging that the responding physicians' overall attitudes and perceptions concerning API pollution in environment as well as EDSP under an EPV perspective were positive (table 3), which would shape the motivation for the future practice. In recent years, along with the increasingly serious environmental pollution which has attracted the particular attention of Chinese government, the environmental awareness and initiatives of Chinese people have gradually been awakened.¹⁴ Accordingly, most Chinese physician respondents showed their concerns about the environment problems caused by APIs. A majority of physicians agreed the existence, potential risks of APIs in environment and the effectiveness of EDSP under an EPV perspective in decreasing environmental exposure of excreted APIs. Most respondents posed the eco-responsible attitudes and perceived their own responsibility for the control of API pollution linked to the medical prescriptions as well as the implementation of EDSP under an EPV perspective, and importantly, expressed their willingness to participate in EDSP and EPV activities.

Our survey data suggested that the environmental consciousness of Chinese physicians during prescribing was insufficient, which was demonstrated by the finding that no respondent identified the environmental impacts as the aspects regarding medicines affecting his(her)

prescription decision. The possible reason might be due to the utter lack of the related education or training, which is in alignment with respondents' self-satisfaction with knowledge on EDSP (100% were not satisfied) and respondents' confidence toward EDSP (100% were not confident), considerable portions of respondents who chose 'undecided' option in many Likert-type attitude and perception questions, as well as the conservative wait-and-see attitudes towards EDSP practice held by physicians. 'Poor awareness of EDSP and EPV' was conceived as the most important barrier to the effective implementation of EDSP under the perspective of EPV. Therefore, the environmental sustainability considerations should begin to be included in the physicians' choice of prescription in China, and the long-established norms and guidelines in the practice of clinical prescribing should be accordingly modified under the principle of treating the environment and the patient as an interconnected, integral whole.²⁴ There is a need to optimise the prescribing of drugs with a view to reducing environmental exposure.

In order to explore the possible factors influencing their future EDSP decision making, this survey studied the perceived benefits and concerns of two EDSP approaches, *low-dose prescribing* and *prescribing of drugs possessing environment-friendly excretion profiles*, respectively. Despite the fact that the necessity and benefits of these two EDSP approaches in the aspect of environmental protection were accepted by most responding physicians, the biggest concerns in *low-dose prescribing* and *prescribing of drugs possessing environment-friendly excretion profiles* were the possible negative impact on therapeutic outcomes and too complicated and professional drug evaluation process, respectively. Therefore, during the EDSP design from the perspective of EPV, special emphases should be given on how to ensure the therapeutic efficacy of the 'environment-friendly' doses, and how to standardise and simplify the process of prescribing based on the drugs' environment-friendly excretion profiles.

Moreover, many physicians voiced their concerns about the availability of the related information required in EDSP design. In China, no data system is currently available to guide medical prescribing decisions in the clinical setting for selection of drugs having a low probability of environmental risks and hazards. However, there is a Swedish model which could be used as a reference.^{26 41} Swedish Environmental Classification of Pharmaceuticals developed by Stockholm County Council is a simple and straightforward classification system for prescribing non-environmentally-hazardous drugs, and has been widely used and well accepted among Swedish medical doctors. This easy-to-understand classification classifies the APIs on the Swedish market according to environmental risks and hazards of drugs in view of their persistence, bioaccumulation and toxicity data, and suggests substitution by alternatives with a lower risk or hazard index. We proposed to construct the similar classification system in China, so that physicians who wish to be environmentally conscious in their prescribing could have a reference to

allow them to select the API with the lowest possible environmental impact among the candidates with equivalent therapeutic activities.

Interestingly, as the major challenge for EDSP implementation which was worried about by its advocate Daughton,¹⁵ the issue 'changing the prescribing behaviour of physicians' appeared to be regarded as a small matter by most physicians, because only 21% and 24% respondents chose this item as their concern regarding the *low-dose prescribing* and *prescribing of drugs possessing environment-friendly excretion profiles*, respectively (table 3, Q6 and Q8). Only 6% physician respondents considered the item 'It conflicts with long-accepted prescribing guidelines' as the most major perceived barrier to the effective implementation of EDSP (table 3, Q12). This results suggested that the physicians were willing to change their prescribing habits in order to make their due contributions to control the environmental pollution by APIs.

In addition, we found there was a tendency among the internal medicine physicians to have stronger intentions to attempt EDSP practice than physicians from other specialities, which might be due to their better acquaintance with the pharmacokinetic properties and excretion profile of drugs. There is thus the expectation that it is feasible to first implement EDSP practice from the perspective of EPV in the internal medicine department. Furthermore, nearly half responding physicians were inclined to adopt rational prescribing as the EDSP behaviour that they want to choose first. Rational prescribing is a classical principle concept of drug selection of in the field of personalised treatment or healthcare.³⁰ Based on its high acceptability, further promotion of rational prescribing to control excess medication prescription is a good first approach to implement EPV in the healthcare system to reduce API pollution at the sources. In fact, recent emphasis of rational prescribing has been given to Personalised Healthcare through selection of optimal APIs and determination of individual dosages.²⁶ Personalised adjustment of drug administration holds the potential for enhancing therapeutic outcomes, while simultaneously reducing the environmental risks of APIs.

The main limitation of this study is the sampling bias. This study only enrolled physicians from one province in China, which might weaken the generalisability of results. Moreover, the sample size was not determined by precision analysis technique. Therefore, further studies with larger samples should be conducted to verify our findings.

In conclusion, to the best of our knowledge, this is the first study that explored the physicians' perceptions and attitudes toward EDSP, a sustainable prescription approach to minimise the environmental loads and risks of excreted API residues at their sources. The results suggested that the majority of Chinese physicians had positive attitude towards EDSP. Respondents agreed the existence of APIs in environment, worried about the potential environmental and ecological risks of API residues, supported the effectiveness and necessity of EDSP,

importantly, showed their willingness to participate in the EDSP practices. Nevertheless, at present, the environmental consciousness of Chinese physicians during prescribing is seriously insufficient, which is demonstrated by the finding that no respondent identified the environmental impacts as the aspect regarding medicines affecting his(her) prescription decision, none was satisfied with knowledge on EDSP and showed confidence toward EDSP. The most important barrier to the effective implementation of EDSP was identified as ‘poor awareness of EDSP and EPV’. Accordingly, most responding physicians reported that they held the wait-and-see or conservative attitudes towards EDSP practice. Furthermore, the biggest concerns in *low-dose prescribing* and *prescribing of drugs possessing environment-friendly excretion profiles*, two EDSP approaches, were the possible negative impact on therapeutic outcomes and too complicated and professional drug evaluation process, respectively. In addition, the availability of the related information required in EDSP design was also taken into consideration. An unexpected finding in this survey was that only few respondents were bothered by the issue that EDSP changed the prescribing behaviour of physicians, which was identified as the major challenge for EDSP implementation by its advocate Daughton.¹⁵ This was in line with the responding physicians’ eco-responsible attitudes toward API pollution in environment. Moreover, we found that the internal medicine physicians might be more initiative to engage in EDSP behaviours than the physicians from other specialties.

Based on the above findings, we concluded some recommendations for implementing EDSP from the perspective of EPV:

1. Introducing and strengthening the related medical training and education. Hospitals, medical centres and colleges could develop training and educational programmes to inform physicians prescribing medications and medical students about APIs in environment, the environmental consciousness during prescribing, the environmental impact of their professions, EPV and EDSP.
2. Further promoting rational prescribing to control excess medication prescription, which is a good first approach to implement EPV in the healthcare system based on the survey finding on the respondent physicians’ preferred EDSP behaviours.
3. Integrating the environmental constituent into the rational prescribing principles. Considering the faithfulness of physicians prescribing medicines to rational prescribing principles, this upgraded rational prescribing principle would guide physicians to include environmental sustainability considerations in their practical choice of prescription.
4. Building the database to allow for acquiring the related information to prescribe non-environmentally-hazardous drugs, select the effective and ‘environment-friendly’ doses, understand the drugs’ environment-friendly excretion profiles, and so on. The Swedish

Environmental Classification of Pharmaceuticals could provide helpful sample materials.

5. Constructing the process model of EDSP from the perspective of EPV, in order to ensure the quality, standardisation and convenience of EDSP process.
6. Implementing EDSP practice from the perspective of EPV in the internal medicine department first.

Contributors JW conceived of the original idea for the study, designed the questionnaire, obtained ethical approval, carried out the statistical analysis, drafted the paper and is overall guarantor. SL contributed to the preparation of the data set and interpreted results. BH contributed to the study design, interpretation of results and commented on drafts of the paper.

Funding This work was supported by the National Natural Science Foundation of China (grant numbers 71974153, 81602108); and Humanities and Social Science Foundation from Hubei Provincial Department of Education (grant number 19D014).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval The study was granted approval from the Ethics Committee of Wuhan University of Science and Technology (19068).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No additional data are available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Bingshu He <http://orcid.org/0000-0001-8439-530X>

REFERENCES

- 1 Sato K, Watanabe H, Ikeda T, *et al*. Estimation of total prescription weights of active pharmaceutical ingredients in human medicines based on a public database for environmental risk assessment in Japan. *Regul Toxicol Pharmacol* 2018;99:98–104.
- 2 Ahkola H, Tuominen S, Karlsson S, *et al*. Presence of active pharmaceutical ingredients in the continuum of surface and ground water used in drinking water production. *Environ Sci Pollut Res Int* 2017;24:26778–91.
- 3 Corra L. Chemical pollutants of pharmaceutical origin present in the environment. *J Health Pollut* 2018;8:180916.
- 4 Comber S, Gardner M, Sörme P, *et al*. Active pharmaceutical ingredients entering the aquatic environment from wastewater treatment works: a cause for concern? *Sci Total Environ* 2018;613-614:538–47.
- 5 Blair B, Zimny-Schmitt D, Rudd MA. U.S. news media coverage of pharmaceutical pollution in the aquatic environment: a content analysis of the problems and solutions presented by actors. *Environ Manage* 2017;60:314–22.
- 6 He B-S, Wang J, Liu J, *et al*. Eco-pharmacovigilance of non-steroidal anti-inflammatory drugs: necessity and opportunities. *Chemosphere* 2017;181:178–89.
- 7 Wang J, He B, Yan D, *et al*. Implementing ecopharmacovigilance (EPV) from a pharmacy perspective: a focus on non-steroidal anti-inflammatory drugs. *Sci Total Environ* 2017;603-604:772–84.
- 8 Holm G, Snape JR, Murray-Smith R, *et al*. Implementing ecopharmacovigilance in practice: challenges and potential opportunities. *Drug Saf* 2013;36:533–46.
- 9 Yu X, Hu X, Li S, *et al*. Attitudes and practice regarding disposal for unwanted medications among young adults and elderly people in China from an Ecopharmacovigilance perspective. *Int J Environ Res Public Health* 2019;16. doi:10.3390/ijerph16081463. [Epub ahead of print: 25 Apr 2019].
- 10 Medhi B, Sewal RK. Ecopharmacovigilance: an issue urgently to be addressed. *Indian J Pharmacol* 2012;44:547–9.

- 11 Silva LJG, Lino CM, Meisel LM, *et al.* Selective serotonin re-uptake inhibitors (SSRIs) in the aquatic environment: an ecopharmacovigilance approach. *Sci Total Environ* 2012;437:185–95.
- 12 Wang J, Zhao S-Q, Zhang M-Y, *et al.* Targeted ecopharmacovigilance for ketoprofen in the environment: need, strategy and challenge. *Chemosphere* 2018;194:450–62.
- 13 Wang J, Zhang M-Y, Liu J, *et al.* Using a targeted ecopharmacovigilance intervention to control antibiotic pollution in a rural aquatic environment. *Sci Total Environ* 2019;696:134007.
- 14 Liu J, Wang J, Hu X-M. Knowledge, perceptions, and practice of ecopharmacovigilance among pharmacy professionals in China. *Environ Monit Assess* 2017;189:552.
- 15 Daughton CG. Eco-directed sustainable prescribing: feasibility for reducing water contamination by drugs. *Sci Total Environ* 2014;493:392–404.
- 16 Niemuth NJ, Jordan R, Crago J, *et al.* Metformin exposure at environmentally relevant concentrations causes potential endocrine disruption in adult male fish. *Environ Toxicol Chem* 2015;34:291–6.
- 17 Meijide FJ, Da Cuña RH, Prieto JP, *et al.* Effects of waterborne exposure to the antidepressant fluoxetine on swimming, shoaling and anxiety behaviours of the mosquitofish *Gambusia holbrooki*. *Ecotoxicol Environ Saf* 2018;163:646–55.
- 18 Kümmerer K, Dionysiou DD, Olsson O, *et al.* Reducing aquatic micropollutants - Increasing the focus on input prevention and integrated emission management. *Sci Total Environ* 2019;652:836–50.
- 19 Machado KC, Grassi MT, Vidal C, *et al.* A preliminary nationwide survey of the presence of emerging contaminants in drinking and source waters in Brazil. *Sci Total Environ* 2016;572:138–46.
- 20 Praveena SM, Shaifuddin SNM, Sukiman S, *et al.* Pharmaceuticals residues in selected tropical surface water bodies from Selangor (Malaysia): occurrence and potential risk assessments. *Sci Total Environ* 2018;642:230–40.
- 21 Sorensen JPR, Lapworth DJ, Nkhuwa DCW, *et al.* Emerging contaminants in urban groundwater sources in Africa. *Water Res* 2015;72:51–63.
- 22 Sposito JCV, Montagner CC, Casado M, *et al.* Emerging contaminants in Brazilian rivers: occurrence and effects on gene expression in zebrafish (*Danio rerio*) embryos. *Chemosphere* 2018;209:696–704.
- 23 Yi X, Tran NH, Yin T, *et al.* Removal of selected PPCPs, EDCs, and antibiotic resistance genes in landfill leachate by a full-scale constructed wetlands system. *Water Res* 2017;121:46–60.
- 24 Frédéric O, Yves P. Pharmaceuticals in hospital wastewater: their ecotoxicity and contribution to the environmental hazard of the effluent. *Chemosphere* 2014;115:31–9.
- 25 Daughton CG. The Matthew effect and widely prescribed pharmaceuticals lacking environmental monitoring: case study of an exposure-assessment vulnerability. *Sci Total Environ* 2014;466–467:315–25.
- 26 Straub JO. Reduction in the environmental exposure of pharmaceuticals through diagnostics, personalised healthcare and other approaches. A mini review and discussion paper. *Sustain Chem Pharm* 2016;3:1–7.
- 27 Blair BD. Potential upstream strategies for the mitigation of pharmaceuticals in the aquatic environment: a brief review. *Curr Environ Health Rep* 2016;3:153–60.
- 28 Daughton CG, Ruhoy IS. Green pharmacy and pharmEcovigilance: prescribing and the planet. *Expert Rev Clin Pharmacol* 2011;4:211–32.
- 29 Daughton CG, Ruhoy IS. Lower-dose prescribing: minimizing "side effects" of pharmaceuticals on society and the environment. *Sci Total Environ* 2013;443:324–37.
- 30 Maxwell SRJ. Rational prescribing: the principles of drug selection. *Clin Med* 2016;16:459–64.
- 31 Ding B. Pharma industry 4.0: literature review and research opportunities in sustainable pharmaceutical supply chains. *Proc Saf Environ Protection* 2018;119:115–30.
- 32 Singer AC, Xu Q, Keller VDJ. Translating antibiotic prescribing into antibiotic resistance in the environment: a hazard characterisation case study. *PLoS One* 2019;14:e0221568.
- 33 International Pharmaceutical Federation. *Green pharmacy practice: taking responsibility for the environmental impact of medicines*. The Hague, Netherlands: International Pharmaceutical Federation (FIP), 2015.
- 34 Balch J, Schoen JH, Patel PK. Should physicians consider the environmental effects of prescribing antibiotics? *AMA J Ethics* 2017;19:957–65.
- 35 Bashiri FA, Al Shalawi AA, Hamad MH, *et al.* Assessment of physicians knowledge and attitudes in the management of febrile seizures. *Neurosciences* 2018;23:314–9.
- 36 Vogt F, Seidl F, Santarpino G, *et al.* Healthcare IT Utilization and Penetration among Physicians: Novel IT Solutions in Healthcare - Use and Acceptance in Hospitals. *Eur Surg Res* 2018;59:100–13.
- 37 Azuri J, Nashef S. Primary care physicians' characteristics and attitudes on smoking cessation. *Am J Health Behav* 2016;40:578–84.
- 38 Provenzano DA, Kamal KM, Giannetti V. Evaluation of primary care physician chronic pain management practice patterns. *Pain Physician* 2018;21:E593–602.
- 39 Tian Y, Li C, Wang J, *et al.* Modified task-based learning program promotes problem-solving capacity among Chinese medical postgraduates: a mixed quantitative survey. *BMC Med Educ* 2017;17:153.
- 40 Prakash B, Nadig P, Nayak A. Rational prescription for a dermatologist. *Indian J Dermatol* 2016;61:32–8.
- 41 Deblonde T, Hartemann P. Environmental impact of medical prescriptions: assessing the risks and hazards of persistence, bioaccumulation and toxicity of pharmaceuticals. *Public Health* 2013;127:312–7.
- 42 The Ministry of Health of the People's Republic of China. *The 2018 China health statistical yearbook (in Chinese)*. Beijing: Peking Union Medical College Press, 2018.